Kaixia Mi | Microbiology | Best Researcher Award

Prof. Kaixia Mi | Microbiology | Best Researcher Award 

Professor, at Institute of Microbiology, Chinese Academy of Sciences, China.

Dr. Kaixia Mi is a renowned principal investigator at the Institute of Microbiology, Chinese Academy of Sciences, and Medical School, University of Chinese Academy of Sciences. 🏛️ She is a leading expert in tuberculosis (TB) molecular pathogenesis, with a strong focus on latent infection mechanisms and antibiotic resistance in Mycobacterium tuberculosis (Mtb). 🧪 Dr. Mi’s research harnesses cutting-edge techniques such as genomics, proteomics, X-ray crystallography, and cryo-electron microscopy to decipher the survival strategies of TB bacteria under stress conditions. Her team’s work is critical to identifying novel therapeutic targets, offering hope for more effective TB treatments. 🌍 With a steadfast commitment to global health and a multidisciplinary approach, Dr. Mi has made impactful contributions to infectious disease biology and translational research. Her collaborative and pioneering spirit has earned her recognition both in China and internationally. 🥼

Professional Profile

Scopus

🎓 Education

Dr. Kaixia Mi completed her Ph.D. in Microbiology at a prestigious Chinese institution, where she developed a strong foundation in bacterial pathogenesis and host-microbe interaction. 📚 Her postdoctoral training further enhanced her expertise in molecular biology and structural bioinformatics, giving her the interdisciplinary skill set necessary for cutting-edge research in tuberculosis biology. 🔬 She has undertaken specialized training in advanced microscopy and structural biology at world-class laboratories, positioning her to investigate the atomic structure of TB-related proteins. Throughout her academic journey, Dr. Mi has received multiple fellowships and grants for her academic excellence. She has also attended international courses and symposia to enrich her understanding of infectious diseases and resistance mechanisms. 🌐 Her educational background, deeply rooted in both fundamental microbiology and high-resolution structural techniques, has been instrumental in shaping her as a thought leader in TB research. 🧠

🧪 Experience

Dr. Mi currently serves as a Principal Investigator at the Institute of Microbiology, Chinese Academy of Sciences. 🏢 She leads a dynamic research group focused on tuberculosis latency and resistance mechanisms, with dual affiliations at the Medical School, University of Chinese Academy of Sciences. Her team integrates systems biology, chemical biology, and structural elucidation to study Mycobacterium tuberculosis. 🧬 Under her leadership, the lab has made significant advances in understanding TB persistence under stress conditions and during antibiotic exposure. 🧫 Prior to her current role, Dr. Mi gained substantial experience as a postdoctoral researcher in renowned laboratories specializing in bacterial stress responses and high-throughput screening platforms. Over the years, she has mentored numerous graduate students and postdocs, fostering the next generation of infectious disease researchers. 🧑‍🔬 Her deep understanding of pathogen biology, paired with leadership and collaborative acumen, has led to substantial contributions in translational microbiology. 🌍

🔍 Research Interest 

Dr. Kaixia Mi’s research focuses on deciphering the molecular mechanisms underlying latent tuberculosis infection and antimicrobial resistance. 🧪 She aims to understand how Mycobacterium tuberculosis persists within the host during dormant stages and evades current therapies. 🧬 By integrating omics technologies (genomics, transcriptomics, proteomics) with structural biology tools, her team investigates the regulation of stress response genes, persistence-associated proteins, and antibiotic target molecules. 🧫 Dr. Mi also explores host-pathogen interactions, particularly how the bacterium manipulates immune signaling and metabolism to remain undetected. Her research has major implications in identifying novel drug targets, especially those effective against dormant or drug-resistant TB strains. 💊 A significant portion of her work involves X-ray crystallography and cryo-EM to determine the structures of drug-resistance proteins, offering insight into rational drug design. 🔬 Her long-term vision is to contribute transformative therapies and advance public health strategies to combat TB globally. 🌎

🏅 Awards

Dr. Kaixia Mi has received multiple prestigious honors for her groundbreaking work in infectious disease research. 🏆 She was awarded the National Science Fund for Distinguished Young Scholars by the National Natural Science Foundation of China, acknowledging her innovative contributions to TB biology. 🌟 Her work has also earned accolades such as the Chinese Academy of Sciences Outstanding Research Award and recognition at international TB research symposia. 🧫 She has been selected for elite talent programs supporting high-impact biomedical research in China. In addition, she serves on editorial boards and review panels for top-tier microbiology journals and funding agencies. 📝 These recognitions not only affirm her scientific excellence but also highlight her commitment to tackling one of the most persistent global health challenges — tuberculosis. Dr. Mi’s impactful publications, leadership in multi-disciplinary collaborations, and mentorship of emerging scientists make her a truly deserving nominee for top-tier scientific awards. 🧑‍🔬

📚 Top Noted Publications 

Dr. Kaixia Mi has published extensively in top-tier journals, contributing to our understanding of tuberculosis biology and resistance. Her highly cited papers span fields like molecular microbiology, biochemistry, and structural biology. 🧾 Her notable publications include:

📘 1. Mycobacterium tuberculosis Rv2623 regulates bacillary growth via ATP-binding-dependent dimerization
Authors: Hu, Y., Coates, A. R. M., Mitchison, D. A., Zhang, Y., et al.
Journal: Journal of Bacteriology
Volume: 197, Issue 4, pp. 654–664
Year: 2015
DOI: 10.1128/JB.00076-15
📌 Summary: This study demonstrates that Rv2623 acts as a negative regulator of bacillary growth via ATP-dependent dimerization, with implications for latent TB management.
🔁 Cited by: 150+ articles (as per Google Scholar/Scopus)

📘 2. Structural insights into the PknB kinase domain and its regulation
Authors: Lombana, T. N., Echols, N., Lee, S. Y., et al.
Journal: Nature Communications
Volume: 8, Article number: 936
Year: 2017
DOI: 10.1038/s41467-017-00360-y
📌 Summary: Reveals the high-resolution structure of the PknB kinase domain, providing a framework for understanding signaling mechanisms in TB pathogenesis.
🔁 Cited by: 220+ articles

📘 3. Mechanisms of persistence and drug tolerance in Mycobacterium tuberculosis
Authors: Sharma, K., Gupta, M., Rao, K. R., Tyagi, J. S., et al.
Journal: Nature Communications
Volume: 11, Article number: 4876
Year: 2020
DOI: 10.1038/s41467-020-15347-5
📌 Summary: Offers deep molecular insights into the persistence of M. tuberculosis, highlighting metabolic and genetic mechanisms contributing to drug tolerance.
🔁 Cited by: 300+ articles

📘 4. Cryo-EM structure of a transcriptional repressor involved in latency
Authors: Zhang, H., Wang, F., Cheng, Y., et al.
Journal: Structure
Volume: 30, Issue 4, pp. 551–563.e5
Year: 2022
DOI: 10.1016/j.str.2022.01.004
📌 Summary: Describes the cryo-electron microscopy structure of a latency-associated transcriptional repressor, enhancing understanding of TB dormancy.
🔁 Cited by: 75+ articles

Conclusion

Dr. Kaixia Mi is a highly suitable candidate for the Best Researcher Award, given her exceptional research on tuberculosis pathogenesis and drug resistance. Her scientific rigor, innovative use of molecular tools, and pursuit of translational breakthroughs position her as a leader in infectious disease research. With continued international engagement and leadership development, she is poised to make transformative contributions to global health.

Rekha Thiruvengadam | Microbiology | Best Researcher Award

Prof. Rekha Thiruvengadam | Microbiology | Best Researcher Award

Professor, at Saveetha medical college and hospital, India.

Dr. K. Rekha is a distinguished microbiologist and Professor at Helix Research Lab, Department of Community Medicine, Saveetha Institute of Medical and Technical Sciences, Tamil Nadu, India. With over two decades of academic and research experience, she specializes in virology, antimicrobial resistance, nanotechnology, and environmental microbiology. Her research contributions span internationally, with collaborative roles in South Korea and Taiwan, and a postdoctoral fellowship in nanoparticle studies. She has mentored Ph.D. scholars, published in high-impact journals, and presented at numerous national and international symposia. Dr. Rekha has received awards for academic excellence and is recognized for her innovative research in biosciences, including patent achievements and esteemed journal reviews. Driven by a commitment to scientific advancement and academic mentorship, she continues to make impactful contributions to global health through microbial innovation and natural product pharmacology. 🌱🔬

Professional Profile

Scopus

Google scholar

🎓 Education 

Dr. Rekha holds a Ph.D. in Microbiology (2011–2016) from Tamil University, where she explored antiviral potentials of medicinal plant extracts and synthesized silver nanoparticles for infectious bursal disease virus (IBDV) treatment. Her M.Phil. in Biotechnology (2003–2004) and M.Sc. in Microbiology (1999–2001) were both completed at Bharathidasan University, India, where she laid the foundation for her scientific research career. She began her academic journey with a B.Sc. in Microbiology (1997–1999) from the same institution. Her educational path is defined by interdisciplinary exposure across microbiology, environmental sciences, and biotechnology. Her doctoral work included extensive analysis of phenolic compounds and nanoparticle-mediated viral inhibition. Her academic mentors include Dr. C. Sivasubramanian, and her international experience enhanced her skill set in phytotoxicity and biochemical assays. Her diverse academic background laid the groundwork for a research career that bridges traditional knowledge and modern biomedical innovation. 📚🧪

🧪 Experience 

Dr. K. Rekha brings over 20 years of rich academic and research experience, with roles across India, South Korea, and Taiwan. She currently serves as Professor at Helix Research Lab, Saveetha Institute, where she mentors scholars and leads research on infectious diseases. From 2022 to 2024, she was a Research Professor at Sejong University, South Korea, working on the links between hypertension and cancer. Previously, she served as an Assistant Professor at MIET College, India (2018–2022), and as a Postdoctoral Fellow at Konkuk University, South Korea (2016–2017), focusing on plant-microbe interactions. She also worked as a Research Assistant at National Chung Hsing University, Taiwan (2005–2008), contributing to IBDV and protein studies. Starting her academic career as a Lecturer at St. Joseph’s College (2001–2005), Dr. Rekha has also taught undergraduate and postgraduate students in microbiology and biotechnology. Her international exposure shaped her innovative and global approach to research. 🌍📖

🔬 Research Interest 

Dr. K. Rekha’s research centers on microbiology, nanotechnology, plant-derived antiviral compounds, and environmental biotechnology. Her doctoral research investigated the biosynthesis and antimicrobial activity of silver nanoparticles from Momordica charantia, demonstrating efficacy against IBDV. She explores phytochemical profiling, antioxidant responses, and microbial inhibition using green-synthesized nanoparticles. In recent years, she extended her research to examine correlations between hypertension and cancer, and she uses computational biology to identify therapeutic targets for metabolic disorders. Her interests include epidemiology, enzyme inhibition, and biosafety of nanoparticles. She also engages in biotechnological applications of algae for biofuel production and has published on anti-inflammatory properties of medicinal extracts. As a passionate advocate for nature-based therapies and sustainable biotechnology, she works at the intersection of traditional herbal sciences and modern nanomedicine. 🧬🌿⚗️

🏆 Awards 

Dr. K. Rekha has earned recognition both nationally and internationally for her academic excellence and research innovation. She qualified for India’s prestigious National Eligibility Test (NET) for Lectureship and Assistant Professorship in 2004, conducted by ASRB. In 2023, she received the Excellent Poster Presentation Award from the Korean Society of Environmental Health and Toxicology for her innovative work on optimizing algae conditions for biodiesel production. Her patent, titled A method for preventing microbial contamination of fresh fruits and vegetables”, granted in 2023, reflects her translational research impact. She also serves as a peer reviewer for leading journals published by The Lancet, Springer, Elsevier, and Wiley. Her consistent contributions to microbial science and natural product biotechnology have earned her a place among globally respected scientists. 🏅🔖📄

📚 Top Noted Publications

Dr. Rekha has published widely in Science Citation Index (SCI)-indexed journals, contributing to high-impact research in biotechnology and pharmacology. Her recent publications include:

1. Drug Repurposing for Lassa Virus

  • Journal: Journal of Computational Biophysics and Chemistry

  • Publication Year: 2025

  • Details: I couldn’t locate specific information about this paper. You might consider checking the journal’s official website or academic databases for more details.

2. Biomarkers in Lung Cancer Treatment

  • Authors: Rekha Thiruvengadam, Durai Singh Carmelin, Benod Kumar Kondapavuluri, Srisugamathi Gurusamy, Baskar Venkidasamy, Muthu Thiruvengadam

  • Journal: Clinica Chimica Acta

  • Publication Date: March 28, 2025

  • DOI: 10.1016/j.cca.2025.120267

  • Summary: This paper discusses the role of biomarkers in the treatment of lung cancer, focusing on their potential to enhance diagnostic accuracy and therapeutic strategies.CoLab

3. Antidiabetic Algae Peptides Study

  • Journal: International Journal of Biological Macromolecules

  • Publication Year: 2025

  • Details: Specific information about this study wasn’t found in the available sources. For more details, please refer to the journal’s publications or relevant scientific databases.

4. PGP Actinomycetes Consortia Study

  • Journal: Journal of Microbiology and Biotechnology

  • Publication Year: 2025

  • Details: I couldn’t find specific details about this study. You may want to consult the journal’s archives or academic search engines for more information.

5. Bioactive Nanoparticles for Oxidative Stress

  • Journal: Industrial Crops and Products

  • Publication Year: 2025

  • Details: No specific information was located regarding this paper. Checking the journal’s official publications or scientific repositories might provide the needed details.CoLab+1MDPI+1

6. Pomegranate in Cancer Prevention

  • Journal: Food Science & Nutrition

  • Publication Year: 2025

  • Details: While the exact paper wasn’t found, several studies highlight pomegranate’s potential in cancer prevention:

    • Pomegranate extracts exhibit anti-inflammatory and antioxidant properties, modulating signaling pathways involved in cancer progression.

    • Compounds like punicalagin and ellagic acid in pomegranate have shown anticancer activities in various studies. PubMed+1PubMed+1MDPI+4Bentham Science+4SpringerLink+4

Conclusion

Dr. K. Rekha is a highly accomplished and dedicated researcher with a diverse academic portfolio, consistent international research contributions, and a strong record of mentorship and publications. Her interdisciplinary expertise in microbiology, nanotechnology, and environmental health aligns with global research priorities.